Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alpha Tau MedicalDRTS +14.06%28 EV-to-EBITDA is -25.18 as of Jul. 19, 2026. GuruFocus rates DRTS with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 398 Biotechnology companies, Alpha Tau Medical ranks worse than 251256.03% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alpha Tau Medical's enterprise value is $1,162.29 Mil.
Alpha Tau Medical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-46.16 Mil. Therefore, Alpha Tau Medical's EV-to-EBITDA for today is -25.18.
The historical rank and industry rank for Alpha Tau Medical's EV-to-EBITDA or its related term are showing as below:
DRTS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.18 Med: 0 Max: 0
Current: -25.18
DRTS's EV-to-EBITDA is ranked worse than 100% of 398
companies
in the Biotechnology industry
Industry Median: 12.205
vs DRTS: -25.18
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Alpha Tau Medical (NAS:DRTS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alpha Tau Medical's PE Ratio (TTM) for today is calculated as:
Alpha Tau Medical's share price for today is $13.555.
Alpha Tau Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.670.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Alpha Tau Medical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alpha Tau Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Tau Medical EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Tau Medical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alpha Tau Medical's EV-to-EBITDA falls into.
Alpha Tau Medical's current Enterprise Value is $1,162.29 Mil.
Alpha Tau Medical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Tau Medical (DRTS) has a EV-to-EBITDA of -25.18 as of Jul. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alpha Tau Medical. According to the industry distribution chart, Alpha Tau Medical ranks #999999 out of 398 companies in the Biotechnology industry.
Is Alpha Tau Medical's EV-to-EBITDA too high?
Alpha Tau Medical's current EV-to-EBITDA is -25.18. Based on the distribution chart, Alpha Tau Medical ranks #999999 out of 398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alpha Tau Medical has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Tau Medical's EV-to-EBITDA compare to ORIC and OLMA?
According to the Biotechnology industry distribution chart, Alpha Tau Medical ranks #999999 out of 398 companies for EV-to-EBITDA. This places Alpha Tau Medical in the lower half of its industry. The industry median EV-to-EBITDA is 12.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.21, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alpha Tau Medical. For the Biotechnology industry, the median EV-to-EBITDA is 12.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Tau Medical's current EV-to-EBITDA is -25.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Tau Medical stock overvalued right now?
Alpha Tau Medical (DRTS) has a current EV-to-EBITDA of -25.18. The current EV-to-EBITDA is -25.18. Alpha Tau Medical's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Alpha Tau Medical (DRTS), the current EV-to-EBITDA is -25.18 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
28GF Score
Get the complete analysis for DRTS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRTS has been successfully added to your 
